Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Work In Process: 2023

Historic Work In Process for Seres Therapeutics (MCRB) over the last 1 years, with Dec 2023 value amounting to $25.2 million.

  • Seres Therapeutics' Work In Process rose 911.85% to $48.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $48.1 million, marking a year-over-year increase of 911.85%. This contributed to the annual value of $25.2 million for FY2023, which is N/A change from last year.
  • As of FY2023, Seres Therapeutics' Work In Process stood at $25.2 million.
  • Seres Therapeutics' 5-year Work In Process high stood at $25.2 million for FY2023, and its period low was $25.2 million during FY2023.
  • Its 1-year average for Work In Process is $25.2 million, with a median of $25.2 million in 2023.